Tegoprubart Phase 3 Cleared, But Zero Safety Data and Unknown Mechanism Cap Conviction

Eledon Advances Tegoprubart to Phase 3 in Kidney Transplantation

Eledon Pharmaceuticals reported its second quarter 2026 financial results and recent business highlights, marking significant progress in its clinical programs. The company successfully completed an End-of-Phase 2 meeting with the FDA, supporting the advancement of tegoprubart into a global Phase 3 kidney transplantation trial, slated to begin in late 2026. Long-term data from the Phase 2 BESTOW study, presented at ATC 2026, demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared to tacrolimus. Additionally, updated data from an investigator-initiated islet cell transplantation study, presented at ADA 2026, showed 100% insulin independence in all 12 patients with type 1 diabetes. Eledon reported $88.8 million in cash, cash equivalents, and short-term investments as of June 30, 2026.

• Eledon Pharmaceuticals has established the regulatory framework for its planned global Phase 3 trial of tegoprubart in kidney transplantation following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration. This pivotal trial is on track to initiate in late 2026, aiming to enroll approximately 600 patients. The primary endpoint will assess non-inferiority versus tacrolimus at 52 weeks, based on a composite of biopsy-proven acute rejection (BPAR), graft loss, and death.
• New long-term data from the Phase 2 BESTOW clinical program, presented at the American Transplant Congress (ATC) 2026, demonstrated tegoprubart's superior efficacy in kidney transplant patients. At 18 months, patients treated with tegoprubart showed a statistically significant higher mean eGFR of approximately 74 mL/min/1.73 m² compared to 61 mL/min/1.73 m² for tacrolimus (p<0.05). Furthermore, no BPAR events were observed in tegoprubart-treated patients after the first six months post-transplant, contrasting with seven events (9.4%) in the tacrolimus arm.
• Updated data from an investigator-initiated islet cell transplantation study, presented at ADA 2026, highlighted tegoprubart's potential in type 1 diabetes. All 12 patients achieved 100% insulin independence and maintained HbA1c below 6.5%, with a mean most recent HbA1c of approximately 5.4%. The study also reported no severe hypoglycemic episodes post-transplant, stable islet graft function through 22 months, and a favorable tolerability profile without evidence of nephrotoxicity, hypertension, or neurotoxicity.

Eledon's Path to Phase 3 for Tegoprubart in Kidney Transplantation

Kidney transplantation trials have employed diverse designs to capture both efficacy and safety outcomes across immunologically varied patient populations. Key studies range from prospective, open-label, multicenter randomized controlled trials to retrospective analyses, enrolling de novo recipients from donor after circulatory death (DCD), brainstem death (DBD), and extended/expanded criteria donors, with follow-up periods spanning 12 months to over 55 months.

Tegoprubart's Efficacy and Safety vs. Standard of Care

Belatacept, a selective costimulation blocker, has demonstrated superior preservation of renal function and comparable patient and graft survival relative to cyclosporine in Phase III trials, while avoiding the renal toxicities and other adverse events associated with calcineurin inhibitor (CNI) use. Notably, belatacept-treated patients exhibited higher rates of acute rejection than those receiving cyclosporine; however, early, non-recurrent rejection episodes were generally not associated with donor-specific antibodies, and few patients experienced graft loss attributable to rejection. Overall, belatacept's superior glomerular filtration rate outcomes compared with CNIs represent a meaningful clinical advantage, albeit offset by the increased risk of early and histologically severe rejection episodes that require careful monitoring.

Everolimus-based regimens have also been evaluated as alternatives to standard CNI-based immunosuppression. The ATHENA study assessed everolimus combined with reduced CNI exposure versus a standard regimen of mycophenolic acid and tacrolimus in de novo kidney transplant recipients, with the primary objective of demonstrating non-inferiority in renal function — measured by eGFR using the Nankivell formula — at 12 months post-transplantation. Separately, early conversion strategies combining sirolimus with low-dose CNIs are under investigation with the aim of mitigating CNI nephrotoxicity while preserving adequate immunosuppressive efficacy over the long term.

In the context of antibody-mediated rejection (AMR), several targeted agents are being evaluated against or alongside standard-of-care approaches. Eculizumab and ravulizumab, monoclonal antibodies directed against the C5 complement protein, have been employed to prevent AMR in high-risk desensitized patients and as first-line or rescue therapy in established AMR. Additionally, monoclonal anti-interleukin-6 receptor antibody and C1 esterase inhibitor have demonstrated promising signals in pilot studies; however, larger controlled trials remain necessary to fully characterize their safety and efficacy profiles in this indication.

Overcoming Limitations in Current Kidney Transplant Care

Current kidney transplantation care faces a constellation of interconnected clinical challenges that limit long-term graft and patient survival. Despite advances in immunosuppression and transplant medicine, significant gaps remain in the prevention, monitoring, and management of both immunological and non-immunological complications.

• Antibody-mediated rejection (AMR) and donor-specific antibodies (DSA): Approximately 40% of patients with de novo DSA develop biopsy-proven subclinical AMR, yet the pathogenicity of all DSAs remains incompletely understood. Treatment response is highly variable — in one cohort of 18 treated patients, only 44.4% achieved >50% reduction in DSA-MFI or demonstrated stabilization of pathological findings. HLA class I DSAs respond more favorably to plasmapheresis/IVIG desensitization, whereas HLA class II DSAs, particularly anti-DQ antibodies, show inconsistent outcomes. The evidence base remains limited, and further prospective study is required to validate interventions for DSA-positive patients without overt renal dysfunction.

• Suboptimal immunosuppressive drug monitoring: Tacrolimus monitoring via trough concentration (C₀) frequently results in overdosing; AUC-based assessment reveals that tacrolimus is effectively dosed in only 27.8–40.0% of patients on tacrolimus monotherapy and 25.0–31.9% of those on tacrolimus with mycophenolate mofetil. No prospective studies in adult transplant recipients have formally compared clinical outcomes between AUC- and C₀-guided monitoring strategies. Chronic calcineurin inhibitor exposure also contributes to severe arteriolar hyalinosis, compounding long-term allograft injury.

• Post-transplant diabetes mellitus (PTDM): PTDM developed in 23.3% of patients in one reported cohort and was associated with older age, male sex, elevated baseline HbA1c, HDL cholesterol levels, and cumulative 3-month tacrolimus exposure. PTDM negatively affects both graft and patient survival, underscoring the need for early metabolic risk stratification and intervention.

• Multifactorial post-transplant comorbidity burden: Long-term recipients require vigilant surveillance for a broad spectrum of complications — including hyperlipidemia, arterial hypertension, osteoporosis, and progressive renal impairment — alongside early detection of malignancies and opportunistic infections attributable to sustained immunosuppression. The concurrent management of these conditions represents a significant clinical coordination challenge.

• Disease recurrence, particularly IgA nephropathy (IgAN): Recurrent IgAN in kidney transplant recipients appears to adversely affect long-term graft survival, yet both preventive and therapeutic options remain limited. Managing recurrent IgAN alongside calcineurin inhibitor arteriolopathy is particularly complex in long-term allograft care.

• Chronic allograft dysfunction and fibrosis: Progressive interstitial fibrosis and tubular atrophy (IF/TA) driven by both immunological and non-immunological factors remain a leading cause of graft loss. Effective strategies to halt or reverse chronic transplant dysfunction represent a critical unmet need in the field.

Tegoprubart's Dual Promise: Reshaping Transplant Immunosuppression

The journey of transplant medicine has long sought to balance effective immunosuppression with minimizing long-term toxicities. Calcineurin inhibitors (CNIs), while crucial for preventing acute rejection, are known for their adverse effects on renal function, cardiovascular health, and metabolism, ultimately limiting long-term graft survival. The recent progress with tegoprubart, an anti-CD40L antibody, signals a potential shift in this paradigm. Its successful End-of-Phase 2 meeting with the FDA and planned global Phase 3 kidney transplantation trial underscore confidence in its profile.

The long-term data from the Phase 2 BESTOW study are particularly compelling, showing sustained higher kidney function and improved patient-reported outcomes compared to tacrolimus. This suggests tegoprubart could offer a much-needed CNI-sparing or replacement strategy, potentially transforming the standard of care for kidney transplant recipients by improving both graft longevity and quality of life. However, the path forward is not without its challenges. Phase 3 trials must rigorously confirm these benefits in a larger, more diverse population, demonstrating clear superiority or non-inferiority with a superior safety profile against existing therapies. Vigilant monitoring for any signs of thromboembolic events, a historical concern with earlier anti-CD40L agents, will be paramount, despite tegoprubart's design to mitigate this risk.

Beyond kidney transplantation, tegoprubart has shown remarkable promise in islet cell transplantation for type 1 diabetes, achieving 100% insulin independence in an investigator-initiated study. This outcome is a significant milestone, offering hope for a functional cure for type 1 diabetes patients by improving the success and durability of islet grafts. The strategic implications are clear: Eledon is validating a next-generation costimulation blockade platform with broad applicability. Should tegoprubart succeed in Phase 3, it could redefine immunosuppression protocols, not only in solid organ transplantation but also in β-cell replacement therapies, potentially expanding access and improving outcomes for countless patients. The focus will now be on the execution of these pivotal trials and the long-term data that will shape its future.